Results 71 to 80 of about 36,256 (261)

A new perspective on cancer treatment: the interaction and application prospect between ICIs and radiotherapy

Precision Radiation Oncology, EarlyView.
The combination of immune checkpoint inhibitors (ICIs) and radiotherapy synergistically enhances efficacy through an “antigen release‐immune activation” closed‐loop mechanism, significantly improving outcomes in solid tumors (e.g., lung cancer, melanoma).
Guiling Song, Lei Wang, Guopeng Zhao, Song Tan, Xin Liu, Xinghua Li   +5 more
wiley   +1 more source

Interstitial Lung Disease due to Tepotinib after Durvalumab in a Patient with Lung Adenocarcinoma Harbouring MET Exon 14 Skipping Mutation: A Case Report

Case Reports in Oncology
Introduction: Tepotinib is a targeted agent for patients with advanced non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation (METex14).
Ryota Tatsuhige, Keiki Yokoo, Taku Hatakeyama, Takayuki Nagao, Satoshi Ota, Gen Yamada, Hirofumi Chiba   +6 more
doaj   +1 more source

A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)

BMC Cancer, 2020
Background Durvalumab is a standard drug used during maintenance therapy after chemoradiotherapy in patients with locally advanced non-small cell lung cancer (LA-NSCLC).
Kyoichi Kaira, Atsuto Mouri, Shingo Kato, Kenichi Yoshimura, Hiroshi Kagamu, Kunihiko Kobayashi   +5 more
doaj   +1 more source

Multifunctional tumor vaccines carrying thalidomide regulate T cell exhaustion and ferroptosis for immunotherapy strategies

VIEW, EarlyView.
MTV can greatly achieved antigen presenting cell (APCs), and THA will be released from the polyplex core and enhanced antigen presenting, thereby prompting APC maturation and antigen presenting. The membrane antigens on MTV are degraded into small peptides by proteasomes and presented by MHC complexes.
Anmin Huang, Ting Li, Ying Zhou, Sihang Li, Jian Zhang, Yingchao Li, Shijia Wu, Yifan Kong, Zhijie Yu, Jinglin Xia   +9 more
wiley   +1 more source

Cardiotoxicity of immune checkpoint inhibitors [PDF]

, 2017
Cardiac toxicity after conventional antineoplastic drugs (eg, anthracyclines) has historically been a relevant issue. In addition, targeted therapies and biological molecules can also induce cardiotoxicity.
Allison, Atkins, Azuma, Azuma, Baban, Badros, Bellmunt, Bloom, Borghaei, Boussiotis, Boutros, Brahmer, Brahmer, Bretscher, Brunet, Buchbinder, Cardinale, Cardinale, Chen, Chen, Chen, Cooper, Corsello, Costa, Ding, Dong, Dong, Douglas, Dyck, Eigentler, Fehrenbacher, Francisco, Freeman, Freeman, Gagliani, Gangadhar, Garon, Gay, Geisler, Gibson, Goodman, Gordon, Grabie, Hamanishi, Hamid, Hamo, Han, Hathcock, Heinzerling, Herbst, Herbst, Hodi, Hofmann, Huang, Hurst, Jain, Johnson, Johnson, Johnston, Keir, Khan, Koelzer, Lacouture, Larkin, Lasaro, Latchman, Le Mercier, Le Mercier, Leach, Lesokhin, Lines, Linsley, Linsley, Lucas, Läubli, Mahoney, Martin, Matsuzaki, Menzies, Michot, Mohme, Moslehi, Moynihan, Naidoo, Nayak, Nghiem, Nguyen, Ni, Nishimura, Nishimura, Okamura, Okazaki, Okazaki, Pardoll, Peggs, Pitt, Postow, Powles, Prashanth, Ribas, Rittmeyer, Rizvi, Robert, Robert, Roth, Sakuishi, Semper, Sharma, Sharma, Sheppard, Sivan, Smyth, Spain, Stanietsky, Suter, Tadokoro, Tadokoro, Tarrio, Tivol, Tocchetti, Tocchetti, Topalian, Topalian, Tumeh, Voskens, Vétizou, Wang, Wang, Watanabe, Waterhouse, Weber, Westin, Wing, Wolchok, Woo, Yan, Yeh, Yokosuka, Yu, Yun, Zitvogel   +140 more
core   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

Rising incidence of radiation pneumonitis after adjuvant durvalumab in NSCLC patients treated with concurrent chemoradiotherapy

Acta Oncologica
Background and purpose: Adding adjuvant durvalumab to chemoradiotherapy (CRT) improves overall survival (OS) rates in locally advanced Non-Small-Cell Lung Cancer (NSCLC).
Rutger H. Stoffers, Anne G.H. Niezink, Olga Chouvalova, Jan F. Ubbels, Marleen Woltman-van Iersel, T. Jeroen N. Hiltermann, Lucie B.M. Hijmering-Kappelle, Gea Douma, Sander M. de Hosson, John W.G. van Putten, Friso T. Zandberg, Lisanne V. van Dijk, Johannes A. Langendijk, Robin Wijsman   +13 more
doaj   +1 more source

Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma

Alimentary Pharmacology &Therapeutics, EarlyView.
Patients who received immune checkpoint inhibitors before liver transplant for the treatment of hepatocellular carcinoma had rejection and survival outcomes comparable to those without ICI exposure. Most rejection episodes were effectively managed with medical therapy.
L. Aceituno, C. Magyar, P. Tabrizian, R. Marino, K. Watt, D. Chascsa, G. Schnickel, V. Banz, F. Alconchel, Celia Martagon, C. Moctezuma, T. Baker, C. Nwaduru, F. J. Krendl, R. Oberhuber, L. Ruiz‐Ortega, C. Demers, R. Bucur, G. O'Kane, A. Vogel, B. Mínguez, G. Sapisochin   +21 more
wiley   +1 more source

Targeting the tumor microenvironment in colorectal peritoneal metastases

, 2020
Peritoneal metastasis (PM) occurs in approximately one in four colorectal cancer (CRC) patients. The pathophysiology of colorectal PM remains poorly characterized. Also, the efficacy of current treatment modalities, including surgery and intraperitoneal (
Ceelen, Wim, De Wever, Olivier, Heriot, Alexander G., Narasimhan, Vignesh, Ramsay, Robert G.   +4 more
core   +1 more source

Immuunravi – uus suund onkoloogias [PDF]

, 2017
Kasvaja mikrokeskkonnas ekspresseeritakse mitmeid immuunreaktsioone mõjutavaid molekule ning seda nii immuunsüsteemi kui ka kasvajarakkude endi poolt.
Jaal, Jaanika, Jaal, Jana, Junninen, Jelizaveta, Kase, Marju, Niinepuu, Kristi, Saar, Marika   +5 more
core   +2 more sources